Akebia Therapeutics Q3 EPS $(0.08), Inline, Sales $42.05M Miss $48.18M Estimate
Portfolio Pulse from Benzinga Newsdesk
Akebia Therapeutics reported Q3 earnings per share (EPS) of $(0.08), in line with analyst consensus. However, the company's sales of $42.05M missed the estimated $48.18M. This represents a 71.43% increase in losses from the same period last year and a 14.12% decrease in sales.
November 08, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Akebia Therapeutics' Q3 earnings were in line with estimates, but sales missed expectations.
Akebia Therapeutics' Q3 earnings were in line with analyst expectations, which is positive. However, the company's sales missed the consensus estimate, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100